TY - JOUR
T1 - Unravelling the Sequential Interplay of Mutational Mechanisms during Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia
AU - Antić, Željko
AU - Lelieveld, Stefan H
AU - van der Ham, Cédric G
AU - Sonneveld, Edwin
AU - Hoogerbrugge, Peter M
AU - Kuiper, Roland P
N1 - Publisher Copyright:
© 2021 by the authors.
PY - 2021/2/2
Y1 - 2021/2/2
N2 - Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy and is characterized by clonal heterogeneity. Genomic mutations can increase proliferative potential of leukemic cells and cause treatment resistance. However, mechanisms driving mutagenesis and clonal diversification in ALL are not fully understood. In this proof of principle study, we performed whole genome sequencing of two cases with multiple relapses in order to investigate whether groups of mutations separated in time show distinct mutational signatures. Based on mutation allele frequencies at diagnosis and subsequent relapses, we clustered mutations into groups and performed cluster-specific mutational profile analysis and de novo signature extraction. In patient 1, who experienced two relapses, the analysis unraveled a continuous interplay of aberrant activation induced cytidine deaminase (AID)/apolipoprotein B editing complex (APOBEC) activity. The associated signatures SBS2 and SBS13 were present already at diagnosis, and although emerging mutations were lost in later relapses, the process remained active throughout disease evolution. Patient 2 had three relapses. We identified episodic mutational processes at diagnosis and first relapse leading to mutations resembling ultraviolet light-driven DNA damage, and thiopurine-associated damage at first relapse. In conclusion, our data shows that investigation of mutational processes in clusters separated in time may aid in understanding the mutational mechanisms and discovery of underlying causes.
AB - Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy and is characterized by clonal heterogeneity. Genomic mutations can increase proliferative potential of leukemic cells and cause treatment resistance. However, mechanisms driving mutagenesis and clonal diversification in ALL are not fully understood. In this proof of principle study, we performed whole genome sequencing of two cases with multiple relapses in order to investigate whether groups of mutations separated in time show distinct mutational signatures. Based on mutation allele frequencies at diagnosis and subsequent relapses, we clustered mutations into groups and performed cluster-specific mutational profile analysis and de novo signature extraction. In patient 1, who experienced two relapses, the analysis unraveled a continuous interplay of aberrant activation induced cytidine deaminase (AID)/apolipoprotein B editing complex (APOBEC) activity. The associated signatures SBS2 and SBS13 were present already at diagnosis, and although emerging mutations were lost in later relapses, the process remained active throughout disease evolution. Patient 2 had three relapses. We identified episodic mutational processes at diagnosis and first relapse leading to mutations resembling ultraviolet light-driven DNA damage, and thiopurine-associated damage at first relapse. In conclusion, our data shows that investigation of mutational processes in clusters separated in time may aid in understanding the mutational mechanisms and discovery of underlying causes.
KW - APOBEC Deaminases/genetics
KW - Alleles
KW - Child
KW - Child, Preschool
KW - Clonal Evolution/genetics
KW - DNA Damage/drug effects
KW - DNA Mutational Analysis
KW - Female
KW - Gene Expression Regulation, Neoplastic
KW - Gene Frequency
KW - Genetic Heterogeneity
KW - High-Throughput Nucleotide Sequencing
KW - Humans
KW - Male
KW - Mutagenesis/genetics
KW - Mutation/genetics
KW - Pediatrics
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
KW - Whole Genome Sequencing
UR - http://www.scopus.com/inward/record.url?scp=85100547297&partnerID=8YFLogxK
U2 - 10.3390/genes12020214
DO - 10.3390/genes12020214
M3 - Article
C2 - 33540666
SN - 2073-4425
VL - 12
SP - 1
EP - 12
JO - Genes
JF - Genes
IS - 2
M1 - 214
ER -